Clinical trial
A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
NCT00073125 is registered in ClinicalTrials.gov with Abbott as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
- Lead sponsor
- Abbott
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2003
- Completion date
- Not reported
- Enrollment
- 103 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.